Drug intelligence / Profile preview

STI-2030

Development stage: Preclinical
Lead developer: Sorrento Therapeutics

Overview

STI-2030 is a Sorrento Therapeutics investigational drug candidate reported in pipeline databases as a preclinical or pending program for infectious and respiratory diseases, with COVID-19 listed as an indication. Publicly accessible source material does not clearly disclose its molecular identity, specific modality, target, or mechanism of action. Based on the limited available evidence, it appears to have been an early-stage Sorrento development code rather than an approved or clinically characterized product, and the program does not appear to have advanced to a publicly documented clinical stage.

Beyond the preview

Go deeper on STI-2030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STI-2030.

Explore the full profile